Ask AI

Test First, Treat Right: Advancing ROS1 Detection and Targeted Therapy Selection in NSCLC

Start Activity
Video
Video Start Activity
This activity is available for 1.00 CME/CE credit(s).

Released: November 03, 2026

Expiration: May 02, 2027

See Activity Collection

Step 1 of 5

1 Pre Assessment 2 Video 3 Post Assessment 4 Evaluation 5 Credit

In this on-demand webcast, experts discuss how advances in biomarker testing and targeted therapy are reshaping the management of ROS1-rearranged non-small-cell lung cancer (NSCLC). Through a practical review of the latest clinical evidence, experts explore strategies for identifying ROS1 fusions, selecting and sequencing available and emerging ROS1-targeted therapies, and balancing efficacy, intracranial activity, and treatment-related toxicities when individualizing care. The discussion also examines approaches to disease progression and acquired resistance, including the ROS1 G2032R mutation and other on- and off-target resistance mechanisms. Learners will gain insights into how molecular testing, CNS involvement, resistance profiles, and patient-specific considerations can be integrated into treatment decisions across the continuum of care for patients with ROS1-rearranged NSCLC.

Benjamin Levy
Benjamin Levy, MD, FASCO
Samuel Rosner
Samuel Rosner, MD
ROS1 in NSCLC

Pre Assessment

Assess your current knowledge and clinical approach before beginning your video.
Begin Your Video
1.

How many people with NSCLC do you provide care for in a typical month?

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

At what point are multidisciplinary discussions about biomarker testing most commonly initiated at your institution for patients with newly diagnosed advanced NSCLC?

4.

Which aspect of your institution’s multidisciplinary workflow for biomarker testing in newly diagnosed advanced NSCLC presents the greatest challenge?

5.

In your current practice, how often do you ensure testing for ROS1 rearrangements has been completed?

6.

  • A 52-yr-old woman with ROS1-rearranged NSCLC received crizotinib as initial therapy and experienced widespread disease progression; a new biopsy of the liver metastases and NGS testing discovered an acquired ROS1 G2032R mutation

  • She was transitioned to repotrectinib, although she had a partial response at her 6-wk follow-up, she developed grade 3 dizziness, gait instability, and cognitive impairment​

  • Repotrectinib was withheld due to the adverse events

What treatment should be considered for this patient?

Begin Your Video